Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CVAC – CureVac N.V.

Float Short %

0.78

Margin Of Safety %

1

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.16

EPS Last/This Y

-1.32

EPS This/Next Y

0.04

Price

5.43

Target Price

6.21

Analyst Recom

2.71

Performance Q

30.77

Relative Volume

0.29

Beta

2.53

Ticker: CVAC




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25CVAC5.470.360.003857
2025-07-28CVAC5.430.360.083856
2025-07-29CVAC5.410.360.103921
2025-07-30CVAC5.430.360.203910
2025-07-31CVAC5.390.360.403909
2025-08-01CVAC5.410.350.173913
2025-08-04CVAC5.470.350.003918
2025-08-05CVAC5.480.350.073922
2025-08-06CVAC5.440.350.003924
2025-08-07CVAC5.450.350.003923
2025-08-08CVAC5.440.340.004001
2025-08-11CVAC5.430.340.194017
2025-08-12CVAC5.470.340.094054
2025-08-13CVAC5.510.340.024132
2025-08-14CVAC5.510.340.024163
2025-08-15CVAC5.490.330.004197
2025-08-18CVAC5.450.340.003898
2025-08-19CVAC5.460.330.004010
2025-08-20CVAC5.450.310.004115
2025-08-21CVAC5.430.310.004185
2025-08-22CVAC5.430.300.044215
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25CVAC5.4642.6-343.6-0.49
2025-07-28CVAC5.4342.6-342.5-0.49
2025-07-29CVAC5.4142.6-342.9-0.49
2025-07-30CVAC5.4242.6-342.1-0.49
2025-07-31CVAC5.3942.6-342.1-0.49
2025-08-01CVAC5.4142.6-343.1-0.49
2025-08-04CVAC5.4642.6-344.4-0.49
2025-08-05CVAC5.4742.6-343.2-0.49
2025-08-06CVAC5.4442.6-341.3-0.49
2025-08-07CVAC5.4642.6-342.5-0.49
2025-08-08CVAC5.4442.6-342.0-0.49
2025-08-11CVAC5.4342.6-342.2-0.49
2025-08-12CVAC5.4642.6-343.3-0.49
2025-08-13CVAC5.5042.6-343.2-0.49
2025-08-14CVAC5.5142.6-342.5-0.49
2025-08-15CVAC5.4942.6-342.1-0.49
2025-08-18CVAC5.4642.6-341.8-0.49
2025-08-19CVAC5.46-93.6-352.8-0.49
2025-08-20CVAC5.45-93.6-352.1-0.49
2025-08-21CVAC5.42-93.6-351.5-0.49
2025-08-22CVAC5.43-93.6-352.5-0.49
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25CVAC0.001.361.11
2025-07-28CVAC0.00-0.711.11
2025-07-29CVAC0.00-0.711.11
2025-07-30CVAC0.00-0.711.11
2025-07-31CVAC0.00-0.711.11
2025-08-01CVAC0.00-0.711.11
2025-08-04CVAC0.00-0.521.11
2025-08-05CVAC0.00-0.521.11
2025-08-06CVAC0.00-0.521.11
2025-08-07CVAC0.00-0.521.11
2025-08-08CVAC0.00-0.521.11
2025-08-11CVAC0.00-0.511.11
2025-08-12CVAC0.00-0.510.78
2025-08-13CVAC0.00-0.510.78
2025-08-14CVAC0.00-0.510.78
2025-08-15CVAC0.00-0.510.78
2025-08-18CVAC0.006.510.78
2025-08-19CVAC0.006.510.78
2025-08-20CVAC0.006.510.78
2025-08-21CVAC0.006.510.78
2025-08-22CVAC0.006.510.78
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.3

Avg. EPS Est. Current Quarter

0.1

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

6.51

Beta

2.53

Average Sales Estimate Current Quarter

34

Average Sales Estimate Next Quarter

32

Fair Value

5.51

Quality Score

100

Growth Score

54

Sentiment Score

80

Actual DrawDown %

96.4

Max Drawdown 5-Year %

-98.3

Target Price

6.21

P/E

6.03

Forward P/E

PEG

P/S

2.13

P/B

1.75

P/Free Cash Flow

7.67

EPS

0.9

Average EPS Est. Cur. Y​

-0.49

EPS Next Y. (Est.)

-0.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.42

Relative Volume

0.29

Return on Equity vs Sector %

8.3

Return on Equity vs Industry %

21.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-352.5
CureVac N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 825
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in TĂĽbingen, Germany.
stock quote shares CVAC – CureVac N.V. Stock Price stock today
news today CVAC – CureVac N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch CVAC – CureVac N.V. yahoo finance google finance
stock history CVAC – CureVac N.V. invest stock market
stock prices CVAC premarket after hours
ticker CVAC fair value insiders trading